KR20220082934A - 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법 - Google Patents

지연된 약물전달 임플란트에 의한 눈 질환의 치료방법 Download PDF

Info

Publication number
KR20220082934A
KR20220082934A KR1020227018854A KR20227018854A KR20220082934A KR 20220082934 A KR20220082934 A KR 20220082934A KR 1020227018854 A KR1020227018854 A KR 1020227018854A KR 20227018854 A KR20227018854 A KR 20227018854A KR 20220082934 A KR20220082934 A KR 20220082934A
Authority
KR
South Korea
Prior art keywords
implant
eye
biodegradable
months
plga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227018854A
Other languages
English (en)
Korean (ko)
Inventor
제인-구오 시아
라훌 바가트
웬디 엠. 블랜다
티에리 니바지올리
린 펭
데이비드 초우
데이비드 에이. 웨버
Original Assignee
알레간 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52001114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20220082934(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알레간 인코포레이티드 filed Critical 알레간 인코포레이티드
Priority to KR1020247013455A priority Critical patent/KR20240058976A/ko
Publication of KR20220082934A publication Critical patent/KR20220082934A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
KR1020227018854A 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법 Ceased KR20220082934A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247013455A KR20240058976A (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361904887P 2013-11-15 2013-11-15
US61/904,887 2013-11-15
PCT/US2014/065804 WO2015073895A1 (en) 2013-11-15 2014-11-14 Methods of treatment of ocular conditions with a sustained drug delivery implant
KR1020167015466A KR102475746B1 (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167015466A Division KR102475746B1 (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247013455A Division KR20240058976A (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법

Publications (1)

Publication Number Publication Date
KR20220082934A true KR20220082934A (ko) 2022-06-17

Family

ID=52001114

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227018854A Ceased KR20220082934A (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법
KR1020167015466A Active KR102475746B1 (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법
KR1020247013455A Ceased KR20240058976A (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020167015466A Active KR102475746B1 (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법
KR1020247013455A Ceased KR20240058976A (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법

Country Status (24)

Country Link
US (2) US20150140062A1 (enExample)
EP (2) EP3714875A1 (enExample)
JP (2) JP6675307B2 (enExample)
KR (3) KR20220082934A (enExample)
CN (1) CN105764517A (enExample)
AU (4) AU2014348369B2 (enExample)
CA (1) CA2929689A1 (enExample)
CL (1) CL2016001167A1 (enExample)
CY (1) CY1123344T1 (enExample)
DK (1) DK3068403T3 (enExample)
ES (1) ES2819215T5 (enExample)
HU (1) HUE050913T2 (enExample)
IL (2) IL245548A0 (enExample)
MX (2) MX2016006334A (enExample)
MY (1) MY176039A (enExample)
NZ (1) NZ719953A (enExample)
PH (1) PH12016500869B1 (enExample)
PL (1) PL3068403T3 (enExample)
PT (1) PT3068403T (enExample)
RU (1) RU2690841C1 (enExample)
SG (1) SG10201809363SA (enExample)
SI (1) SI3068403T1 (enExample)
UA (1) UA122117C2 (enExample)
WO (1) WO2015073895A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115337254A (zh) * 2015-07-23 2022-11-15 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
AU2017321980B2 (en) 2016-09-02 2020-04-30 Alcon Inc. Implant applicators
CA3087238A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
CN111989068B (zh) 2018-05-24 2024-10-25 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CN116133664A (zh) * 2020-07-16 2023-05-16 视觉治疗股份有限公司 含有糖皮质激素的眼部插入物
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantable device for the delayed release of a macromolecular drug compound
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US6699493B2 (en) 2000-11-29 2004-03-02 Oculex Pharmaceuticals, Inc. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
AU2012214146A1 (en) * 2011-02-11 2013-08-29 Psivida Us, Inc. Methods of treating macular edema using antiedema therapeutics

Also Published As

Publication number Publication date
CA2929689A1 (en) 2015-05-21
US20250319031A1 (en) 2025-10-16
JP2016538292A (ja) 2016-12-08
CL2016001167A1 (es) 2017-01-06
AU2024205640A1 (en) 2024-08-29
DK3068403T3 (da) 2020-09-07
SI3068403T1 (sl) 2020-11-30
KR102475746B1 (ko) 2022-12-08
ES2819215T5 (en) 2026-04-01
US20150140062A1 (en) 2015-05-21
RU2690841C1 (ru) 2019-06-06
CN105764517A (zh) 2016-07-13
RU2016119132A (ru) 2017-12-20
CY1123344T1 (el) 2021-12-31
IL245548A0 (en) 2016-06-30
PH12016500869A1 (en) 2016-07-04
JP7022735B2 (ja) 2022-02-18
KR20240058976A (ko) 2024-05-07
NZ719953A (en) 2022-01-28
PL3068403T3 (pl) 2021-01-11
AU2014348369A1 (en) 2016-06-09
MY176039A (en) 2020-07-22
UA122117C2 (uk) 2020-09-25
AU2024205640B2 (en) 2025-10-23
JP2020055862A (ja) 2020-04-09
ES2819215T3 (es) 2021-04-15
IL290837A (en) 2022-04-01
AU2020204362A1 (en) 2020-07-23
WO2015073895A1 (en) 2015-05-21
HUE050913T2 (hu) 2021-01-28
JP6675307B2 (ja) 2020-04-01
EP3068403B1 (en) 2020-06-17
KR20160085847A (ko) 2016-07-18
PT3068403T (pt) 2020-09-18
AU2022204607A1 (en) 2022-07-21
MX2022002306A (es) 2022-03-25
AU2014348369B2 (en) 2020-04-02
MX2016006334A (es) 2016-09-06
SG10201809363SA (en) 2018-11-29
EP3714875A1 (en) 2020-09-30
PH12016500869B1 (en) 2016-07-04
EP3068403A1 (en) 2016-09-21
EP3068403B2 (en) 2025-12-03

Similar Documents

Publication Publication Date Title
AU2024205640B2 (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
US20230172948A1 (en) Ocular implant made by a double extrusion proces
JP6132964B2 (ja) 萎縮性加齢性黄斑変性の処置方法
RU2664686C2 (ru) Способ лечения повышенного внутриглазного давления с помощью внутриглазной системы доставки лекарственного средства с замедленным высвобождением
Lee et al. Novel drug delivery systems for retinal diseases: a review
US20150272877A1 (en) Ketorolac-containing sustained release drug delivery systems
RU2015144119A (ru) Ускоренное заживление повреждений глаз с помощью ангиотензиновых пептидов
de Oliveira Dias et al. New drugs and new posterior delivery methods in CME
Pathak-Ray et al. Phaco-endocycloplasty versus phacotrabeculectomy in primary angle-closure glaucoma: a prospective randomized study
Kuppermann et al. Drug delivery to the posterior segment of the eye
HK40038783A (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
HK1228770A1 (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
HK1228770B (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
Ahuja et al. Post-operative assesment of single subconjunctival triamcinolone acetate injection vs topical corticosteroid in cataract surgery: A prospective control study
HK1190092B (en) Bevacizumab for use in a method for treating atrophic age related macular degeneration
HK1183436A (en) Intraocular pressure reduction with intracameral bimatoprost implants

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220603

Application number text: 1020167015466

Filing date: 20160610

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220701

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220726

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230516

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220726

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230516

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230126

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20231123

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20231016

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20230516

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20230126

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20220726

X601 Decision of rejection after re-examination